Probability-based approaches for identifying low-titer antibody responses 1

against SARS-CoV-2 2

3

Xaquín Castro Dopico^{1#}, Leo Hanke^{1°}, Daniel J. Sheward^{1°}, Sandra Muschiol², Soo Aleman³, 4 Nastasiya F. Grinberg⁴, Monika Adori¹, Murray Christian¹, Laura Perez Vidakovics¹, Changil 5 Kim¹, Sharesta Khoenkhoen¹, Pradeepa Pushparaj¹, Ainhoa Moliner Morro¹, Marco 6 Mandolesi¹, Marcus Ahl³, Mattias Forsell⁵, Jonathan Coquet¹, Martin Corcoran¹, Joanna 7

- Rorbach^{6,7}, Joakim Dillner⁸, Gordana Bogdanovic², Gerald M. McInerney¹, Tobias Allander^{1,2}, 8
- Ben Murrell¹, Chris Wallace^{4,9}, Jan Albert^{1,2}, Gunilla B. Karlsson Hedestam^{1#} 9
- 10
- 11 Affiliations:
- 12 ¹Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, 13 Sweden
- 14 ²Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
- 15 ³Department of Infectious Diseases, Karolinska Universitetssjukhuset, Huddinge 141 52, Sweden
- 16 ⁴Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah
- 17 Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, CB2 0AW
- 18 ⁵Department of Clinical Microbiology, Umeå Universitet, Umeå 901 85, Sweden
- 19 ⁶Department of Molecular Biochemistry & Biophysics, Karolinska Institutet, Stockholm 171 77, 20 Sweden
- 21 ⁷Max Planck Institute-Biology of Ageing, Karolinska Institutet Laboratory, Stockholm 171 77, Sweden
- 22 ⁸Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge 141 52, 23 Sweden
- 24 ⁹MRC Biostatistics Unit, University of Cambridge CB2 0SR, United Kingdom
- 25
- 26 °Equal contribution
- 27 #Correspondence
- 28
- 29

31 Abstract

32

33 The levels of the antibody response against SARS-CoV-2 varies widely between individuals, 34 which together with the decline of antibody responses over time, complicates the correct 35 classification of seropositivity using conventional assay cut-offs. All subjects in a cohort of SARS-CoV-2 PCR+ individuals representing different disease severity categories (n=105), and 36 a group of PCR+ hospital staff (n=33), developed IgG against pre-fusion-stabilized spike (S) 37 38 trimers and 97% did against the receptor-binding domain (RBD). The levels differed by several 39 orders of magnitude and associated with disease phenotype. Concomitant analysis of a cohort 40 of healthy blood donors and pregnant women (n=1,000), representing individuals who had 41 undergone milder infections, demonstrated highly variable IgG titers, including several that scored between the classical 3SD and 6SD cut-offs. Since the correct classification of 42 43 seropositivity is critical for epidemiological estimates, we trained probabilistic algorithms to assign likelihood of past infection using anti-S and -RBD IgG data from PCR+ individuals and 44 45 a large cohort of historical negative controls (n=595). Applied to blood donors and pregnant 46 women, this probabilistic approach provided a more accurate way to interpret antibody titers 47 spread over a large continuum offering a probability-based diagnosis. The methods described 48 here are directly applicable to serological measurements following natural infection and 49 vaccination.

50

52 Introduction

53

54 The characterization of nascent SARS-CoV-2-specific antibody responses is critical to our understanding of the infection at both individual and population levels¹. While several studies 55 have reported antibody phenotypes of SARS-CoV-2 infection, consensus on several key issues 56 57 remains outstanding, such as whether all persons who have had the infection develop antibody responses to the virus, what the duration of these responses are following peak responses and 58 what levels provide protective immunity against re-infection^{2–6}. 59

60

Because serological studies have such a central role, both in immunosurveillance and for our 61 62 basic understanding of how humans respond to infection, there is a pressing need for robust and reproducible platforms - and statistical tools - to examine antibody titers of varying levels, 63 as highlighted by the current SARS CoV-2 pandemic⁷. Antibody responses to the virus spike 64 65 glycoprotein are particularly relevant as spike-directed specificities mediate virus neutralizing 66 activity. The great majority of COVID-19 vaccines are based on the spike surface antigen as 67 the goal is to induce neutralizing antibodies that block virus entry into Ace2-positive target cells^{8,9}. There is, therefore, a great need for well-validated assays to monitor both infection and 68 69 immunization-induced antibody responses against SARS-CoV-2 spike, and this will increase further as different spike-based vaccines are introduced world-wide and follow-up studies are 70 71 undertaken to understand the magnitude and quality of responses in different target groups.

72

73 To meet this need, we developed highly sensitive and specific IgM, IgG and IgA ELISAs based 74 on mammalian cell-expressed pre-fusion-stabilized soluble trimers of the SARS-CoV-2 spike 75 (S) glycoprotein and the receptor-binding domain (RBD), and used them in tandem to survey 76 serum samples from large cohort of individuals PCR+ for SARS-CoV-2. For a robust 77 validation of the assays, we used a large set of serum samples from historical blood donors as 78 negative controls (n=595), which is critical for determining the assay background. We then 79 applied these assays to blood donors and pregnant women for whom serostatus was unknown. 80

As we show, and as has been reported by others^{3,10}, the magnitude of response varied greatly 81 between individuals and was associated with disease severity. Those with most pronounced 82 symptoms, as observed in our cohort of hospitalized patients, tended to have very high anti-83 viral antibody titers, while those with asymptomatic or mild disease, represented by randomly 84 85 sampled blood donors and pregnant women, exhibited a range of antibody levels, some of

86 which were high and others that were close to the negative control serum samples, complicating 87 their correct classification.

88

To improve upon the dichotomization of a continuous variable – which is common to many 89 clinical tests but generally results in a loss of information 11,12 – we used tandem anti-S and 90 RBD IgG data from confirmed infections and negative controls to train different probabilistic 91 approaches to identify likelihood of past infection. Compared to strictly thresholding the assay 92 based on standard 3SD or 6SD cut-offs, the more quantitative approaches modelled the 93 94 probability a sample was positive from training responses, improving the identification of low 95 titer values.

96

Results 97

98

Study samples are detailed in Table 1. 99

100

101 Antibody test development

102

103 We developed ELISA protocols to profile IgM, IgG and IgA specific for a pre-fusion conformation stabilized spike (S) glycoprotein trimer¹³, the RBD, and the viral nucleocapsid 104 (N). Trimer conformation was confirmed in each batch by cryo-EM¹⁴ and a representative 105 subset of study samples was used for assay development (Fig. S1A). No reproducible IgG 106 107 reactivity to S or RBD was observed across all 595 historical controls in the study, although 108 two individuals who were PCR-positive for endemic coronaviruses (ECV+) in the last six 109 months displayed robust IgM reactivity to both SARS-CoV-2 N and S, and two 2019 blood 110 donors (from n=72 tested) had low anti-S IgM reactivity (Fig. S1B). Thus, further investigation 111 is required to establish the contribution of potential cross-reactive memory SARS-CoV-2 112 responses¹⁵.

113

114 Our assay revealed a greater than 1,000-fold difference in anti-viral IgG titers between Ab-115 positive individuals when examining serially diluted sera, a wide range difficult to capture in a single test (Fig. S1C). In SARS-CoV-2 PCR+ individuals, anti-viral IgG titers were 116 comparable for S (EC50=3,064; 95% CI [1,197 - 3,626]) and N (EC50=2,945; 95% CI [543 -117 3,936]) and lower for RBD [EC₅₀=1,751; 95% CI 966 - 1,595]. A subset (ca. 10%) of the 118 119 SARS-CoV-2-confirmed individuals did not have detectable IgG responses against the SARS

120 CoV-2 nucleocapsid protein (N) (Fig. S1C), as previously reported¹⁶. Therefore, we did not
121 explore responses to N further.

122

123 <u>Elevated anti-viral Ab titers and neutralizing responses are associated with increased disease</u>
 124 <u>severity</u>

125

126 When screening all SARS-CoV-2 PCR+ individuals from whom clinical information was 127 available (n=105), we detected potent IgG responses against S in 100% of participants, and 128 against RBD in 97% of persons. IgM and IgA responses were generally weaker and more 129 variable and also spread over a large range (Fig. 1A).

130

To examine this further, PCR+ individuals were classified according to their clinical status as 131 132 follows: non-hospitalized; hospitalized or admitted to the intensive care unit. Serum IL-6 levels, a cytokine that feeds Ab production^{17–20}, were increased in severe disease samples (Fig. 133 134 1B). Furthermore, multivariate analyses revealed increased anti-viral IgM, IgG and IgA to also be associated with disease severity, as has been reported³, although IgM was reduced in 135 136 intensive care samples, compared to hospitalized patients (Fig. 1C and S1D-E, Table S1). 137 Severe disease was most associated with virus-specific IgA, suggestive of mucosal pathology. We did not observe an association between ICU or IL-6 status and IgM levels, supporting that 138 139 levels of the cytokine and IgA mark a more severe clinical course of COVID-19 (Fig. S1D). IgA anti-RBD responses were lower in non-hospitalized and hospitalized females compared to 140 141 males, trending similarly for S (Table S1) 10 .

142

Across all PCR+ individuals (sampled up to two months from PCR test), anti-viral IgG levels were maintained, while IgM and IgA decreased, in agreement with their circulating t_{1/2} and viral clearance (Table S1). In longitudinal patient samples (sequential sampling of PCR+ individuals in the study) where we observed seroconversion, IgM, IgG and IgA peaked with similar kinetics when all three isotypes developed, although IgA was not always generated in non-hospitalized or hospitalized individuals (Fig 1D), supporting a more diverse antibody response in severe disease.

150

To extend these observations, we characterized the virus neutralizing Ab response in PCR+ patients. Using a robust *in vitro* pseudotype virus neutralization assay²¹, we detected neutralizing antibodies in the serum of all SARS-CoV-2 PCR+ individuals (from n=48).

154 Neutralizing responses were not seen in samples before seroconversion (Fig. 1D) or negative controls. A large range of neutralizing ID₅₀ titers was apparent, with binding and neutralization 155 being highly correlated (Fig. S1D). In agreement with the binding data, the strongest 156 neutralizing responses were observed in samples from patients in intensive care (g.mean 157 158 ID₅₀=5,058; 95% CI [2,422 - 10,564]) (Fig 1E).

159

160 In healthy blood donors and pregnant women (n=1,000 collected between weeks 17-21, 2020), 161 who did not have signs or symptoms of COVID-19 when they were sampled or two weeks 162 prior to sampling, and had no history of being hospitalized for COVID-19, IgG titers varied greatly but were generally lower than hospitalized COVID-19 patients (Fig. 1F). 163

164

Probabilistic analyses of positivity 165

166

As SARS-CoV-2 results in asymptomatic or mild disease in the majority of cases, and antibody 167 168 titers decline following peak responses, the detection of low titer values is critical to individual 169 and population-level estimates of antibody-positivity. Indeed, many healthy donor test samples 170 screen in this study had optical densities between the 3 and 6 SD cut-offs for both or a single 171 antigen (Fig. 1E), highlighting the problem of assigning case to low responder values.

172

173 To improve our understanding of the assay boundary, we repeatedly analyzed a large number 174 of historical (SARS-CoV-2-negative) controls (blood donors from the spring of 2019, *n*=595) 175 alongside test samples throughout the study (Fig. 2A). We considered the spread of known 176 negative values critical, since the use of a small and unrepresentative set of controls can lead 177 to an incorrectly set threshold, which skews the seropositivity estimate. This is illustrated by 178 the random sub-sampling of non-overlapping groups of negative controls, resulting in a 40% 179 difference in the positivity estimate (Fig. 2B).

180

To exploit individual titers and further improve our statistical estimates, we used anti-S and 181 182 RBD data from PCR+ individuals and negative controls to train probabilistic algorithms to 183 assign likelihood of past infection. A small cohort of PCR+ individuals among Karolinska University Hospital staff (n=33) provided additional training values four months post-PCR 184 185 test.

187 To this end, we compared different probabilistic algorithms – namely, logistic regression (LOG), linear discriminant analysis (LDA), linear support vector machines (SVM) and 188 189 quadratic SVM (SVM2) - suited to ELISA data (Fig. 2C, Materials and Methods). Using ten-190 fold cross validation and training models on both proteins simultaneously (S and RBD), we 191 found all methods worked well, with sensitivity >98% and specificity >99.6% (Fig. 2D). On 192 this metric, LDA gave the highest specificity. Logistic regression had similarly high specificity 193 on some folds of the training data, but with higher sensitivity. We deliberately considered 194 balanced and unbalanced folds (where case:control ratios varied between folds) and found 195 LOG showed the least consistency across strategies, which reflects that the proportion of cases 196 in a sample directly informs a logistic model's estimated parameters. SVM methods had lower 197 specificity than LDA in the training data, but higher sensitivity.

198

199 The standard methods, calling positives by a fixed number of SD above the mean of negative 200 controls, displayed two extreme behaviors: 3-SD had the highest sensitivity (100%) while 6-201 SD had the highest specificity, and the lowest sensitivity (Fig. 2D), emphasizing that the 202 number of SD above the mean is a key parameter, but one which is not learnt in any formal 203 data-driven manner. Both SVM and LDA offer linear classification boundaries, but we can see 204 that the probability transition from negative to positive cases is much sharper for LDA (Fig. 205 2C) – potentially resulting in false negatives when applied to the test data, but giving the model 206 high specificity in the training data under cross-validation. SVM exhibits a softer probability 207 transition around its classification boundary, offering a much more nuanced approach to the 208 points lying in the mid-range of the two proteins. SVM2 creates a nonlinear boundary, but the 209 cross validation suggested that this didn't improve performance relative to linear SVM.

210

211 We chose to create ensemble learners, which were an unweighted average of SVM (linear) or 212 SVM2 (quadratic) and LDA (ENS and ENS2, respectively), as well as a LOG-LDA learner, to balance the benefits of each approach. The ensemble learners seemed to combine the benefits 213 of their parent methods (Fig. 2C). Test data points in the lower right region of each plot are the 214 215 hardest to classify due to the relative scarcity of observations in this region in the training 216 dataset and ENS (SVM-LDA) showed the greatest uncertainty in these regions, appropriately. 217 Given these results, we chose to use ENS (SVM-LDA), with an average sensitivity >99.1% and 218 specificity >99.8%, to analyze the test data.

220 When applied to serology data, the output of ENS is the probability of each sample being antibody-positive. In healthy donor test data, the ENS learner (considering S and RBD 221 responses in an individual sample) estimated 7.8% (95% CI [4.8-12.5]) positivity in samples 222 collected in week 21 of 2020 (Fig. 2E, Table S2). This is in contrast to the SD thresholding, 223 224 which identified 12% and 10% positivity for S and RBD, respectively at 3 SD, and 8% and 7.5, 225 respectively at 6 SD at this time point (Table S2). Therefore, apart from providing more 226 accurate population-level estimates, critical to seroprevalence studies, these approaches have 227 the potential to provide more nuanced information about titers to an individual after an antibody 228 test. For example, the test samples with a 30-60% chance of being antibody positive (Fig. 2E) can be targeted for further investigation. Moreover, such tools are applicable to other clinical 229 230 metrics where a continuous scale is dichotomized and all data and code for implementation is 231 freely available via our online repositories.

232

Discussion 233

234

235 Benefitting from a robust antibody test developed alongside a diagnostic clinical laboratory 236 responsible for monitoring sero-reactivity during the pandemic, we profiled SARS-CoV-2 237 antibody responses in three cohorts of clinical interest. COVID-19 patients receiving intensive care showed the highest anti-viral Ab titers, developing augmented serum IgA and IL-6 with 238 239 worsening disease and more advance respiratory and/or gastrointestinal pathology. These results demonstrate the inflammatory nature of severe COVID-19, and support that cytokine 240 241 and isotype-level measures can help patient monitoring²².

242

243 Importantly, our neutralization data illustrated that nearly all SARS-CoV-2 PCR+ individuals 244 and healthy donors who seroconverted developed neutralizing antibodies capable of preventing 245 S-mediated cell entry, albeit at different titers. These data support that SARS-CoV-2 infection generates a functional B cell response in the majority of people⁶ and serve as a useful 246 247 comparator to titers in response to vaccination.

248

249 Outside of the severe disease setting, it is critical to accurately determine who and how many 250 people have seroconverted for clinical and epidemiological reasons. However, this is 251 complicated by low titer values, which in some cases – and increasingly with time since 252 exposure and in mild disease 23,24 – overlap outlier values among negative control samples. Test 253 samples with true low anti-viral titers fall into this range, highlighting the need to better

254 understand the assay boundary. To improve upon strictly thresholding the assay, we developed 255 probabilistic approaches that characterized uncertainty in individual measures. These and 256 related approaches provide more statistically sound measurements at the level of cohorts and 257 the potential to communicate more nuanced information to individual patients - although the 258 communication of probability needs to be approached with care to ensure what is described 259 matches what an individual interprets. Furthermore, such approaches will aid longitudinal 260 studies of the duration of immunity after SARS-CoV-2 spike-based vaccines and natural infection and facilitate the comparison of responses between different cohorts. 261

262 Materials and methods

263

Human samples and ethical declaration 264

Samples from PCR+ individuals and admitted COVID-19 patients (n=105) were collected by 265 266 the attending clinicians and processed through the Departments of Medicine and Clinical 267 Microbiology at the Karolinska University Hospital. Samples were used in accordance with approval by the Swedish Ethical Review Authority (registration no. 2020-02811). All personal 268 269 identifiers were pseudo-anonymized, and all clinical feature data were blinded to the 270 researchers carrying out experiments until data generation was complete. PCR testing for SARS-CoV-2 RNA was by nasopharyngeal swab or upper respiratory tract sampling at 271 272 Karolinska University Hospital. As viral RNA levels were determined using different qPCR 273 platforms (with the same reported sensitivity and specificity) between participants, we did not 274 analyze these alongside other features. PCR+ individuals (n=105) were questioned about the 275 date of symptom onset at their initial consultation and followed-up for serology during their 276 care, up to 2 months post-diagnosis. Serum from SARS-CoV-2 PCR+ individuals was collected 277 6-61 days post-test, with the median time from symptom onset to PCR being 5 days. In 278 addition, longitudinal samples from 10 of these patients were collected to monitor 279 seroconversion and isotype persistence.

280

281 Hospital workers at Karolinska University Hospital were invited to test for the presence of SARS-CoV-2 RNA in throat swabs in April 2020 and virus-specific IgG in serum in July 2020. 282 283 We screened 33 PCR+ individuals to provide additional training data for ML approaches. All 284 participants provided written informed consent. The study was approved by the National 285 Ethical Review Agency of Sweden (2020-01620) and the work was performed accordingly.

286

287 Anonymized samples from blood donors (n=100/week) and pregnant women (n=100/week) were randomly selected from their respective pools by the department of Clinical 288 289 Microbiology, Karolinska University Hospital. No metadata, such as age or sex information 290 were available for these samples in this study. Pregnant women were sampled as part of routine 291 for infectious diseases screening during the first trimester of pregnancy. Blood donors (*n*=595) 292 collected through the same channels a year previously were randomly selected for use as 293 negative controls. Serum samples from individuals testing PCR+ for endemic coronaviruses, 294 229E, HKU1, NL63, OC43 (n=20, ECV+) in the prior 2-6 months, were used as additional 295 negative controls. The use of study samples was approved by the Swedish Ethical Review

Authority (registration no. 2020-01807). Stockholm County death and Swedish mortality data
was sourced from the ECDC and the Swedish Public Health Agency, respectively. Study
samples are defined in Table 1.

299

300 <u>Serum sample processing</u>

Blood samples were collected by the attending clinical team and serum isolated by the department of Clinical Microbiology. Samples were anonymized, barcoded and stored at -20°C until use. Serum samples were not heat-inactivated for ELISA protocols but were heatinactivated at 56°C for 60 min for neutralization experiments.

305

306 <u>SARS-CoV-2 antigen generation</u>

The plasmid for expression of the SARS-CoV-2 prefusion-stabilized spike ectodomain with a C-terminal T4 fibritin trimerization motif was obtained from¹³. The plasmid was used to transiently transfect FreeStyle 293F cells using FreeStyle MAX reagent (Thermo Fisher Scientific). The ectodomain was purified from filtered supernatant on Streptactin XT resin (IBA Lifesciences), followed by size-exclusion chromatography on a Superdex 200 in 5 mM Tris pH 8, 200 mM NaCl.

313

The RBD domain (RVQ – QFG) of SARS-CoV-2 was cloned upstream of a Sortase A recognition site (LPETG) and a 6xHIS tag, and expressed in 293F cells as described above. RBD-HIS was purified from filtered supernatant on His-Pur Ni-NTA resin (Thermo Fisher Scientific), followed by size-exclusion chromatography on a Superdex 200. The nucleocapsid was purchased from Sino Biological.

319

320 Anti-SARS-CoV-2 ELISA

321 96-well ELISA plates (Nunc MaxiSorp) were coated with SARS-CoV-2 S trimers, RBD or nucleocapsid (100 µl of 1 ng/µl) in PBS overnight at 4°C. Plates were washed six times with 322 PBS-Tween-20 (0.05%) and blocked using PBS-5% no-fat milk. Human serum samples were 323 thawed at room temperature, diluted (1:100 unless otherwise indicated), and incubated in 324 325 blocking buffer for 1h (with vortexing) before plating. Serum samples were incubated 326 overnight at 4°C before washing, as before. Secondary HRP-conjugated anti-human antibodies were diluted in blocking buffer and incubated with samples for 1 hour at room temperature. 327 328 Plates were washed a final time before development with TMB Stabilized Chromogen 329 (Invitrogen). The reaction was stopped using 1M sulphuric acid and optical density (OD)

330 values were measured at 450 nm using an Asys Expert 96 ELISA reader (Biochrom Ltd.). Secondary antibodies (all from Southern Biotech) and dilutions used: goat anti-human IgG 331 (2014-05) at 1:10,000; goat anti-human IgM (2020-05) at 1:1000; goat anti-human IgA (2050-332 05) at 1:6,000. All assays of the same antigen and isotype were developed for their fixed time 333 334 and samples were randomized and run together on the same day when comparing binding 335 between PCR+ individuals. Negative control samples were run alongside test samples in all 336 assays and raw data were log transformed for statistical analyses.

337

338 In vitro virus neutralisation assay

Pseudotyped viruses were generated by the co-transfection of HEK293T cells with plasmids 339 340 encoding the SARS-CoV-2 spike protein harboring an 18 amino acid truncation of the cytoplasmic tail¹³; a plasmid encoding firefly luciferase; a lentiviral packaging plasmid 341 (Addgene 8455) using Lipofectamine 3000 (Invitrogen). Media was changed 12-16 hours post-342 343 transfection and pseudotyped viruses harvested at 48- and 72-hours, filtered through a 0.45 µm 344 filter and stored at -80°C until use. Pseudotyped neutralisation assays were adapted from 345 protocols validated to characterize the neutralization of HIV, but with the use of HEK293T-346 ACE2 cells. Briefly, pseudotyped viruses sufficient to generate ~100,000 RLUs were incubated 347 with serial dilutions of heat-inactivated serum for 60 min at 37°C. Approximately 15,000 HEK293T-ACE2 cells were then added to each well and the plates incubated at 37°C for 48 348 hours. Luminescence was measured using Bright-Glo (Promega) according to the 349 manufacturer's instructions on a GM-2000 luminometer (Promega) with an integration time of 350 351 0.3s. The limit of detection was at a 1:45 serum dilution.

352

353 IL-6 cytometric bead array

Serum IL-6 levels were measured in a subset of PCR+ serum samples (n=64) using an 354 355 enhanced sensitivity cytometric bead array against human IL-6 from BD Biosciences (Cat # 561512). Protocols were carried out according to the manufacturer's recommendations and 356 357 data acquired using a BD Celesta flow cytometer.

358

359 Statistical analysis of SARS-CoV-2 PCR+ data

All univariate comparisons were performed using non-parametric analyses (Kruskal-Wallis, 360 stratified Mann-Whitney, hypergeometric exact tests and Spearman rank correlation), as 361 indicated, while multivariate comparisons were performed using linear regression of log 362 363 transformed measures and Wald tests. For multivariate tests, all biochemical measures (IL-6,

364 PSV ID50 neut., IgG, IgA, IgM) were log transformed to improve the symmetry of the distribution. As "days since first symptom" and "days since PCR+ test" are highly correlated, 365 we cannot include both in any single analysis. Instead, we show results for one, then the other 366 (Supp. Table 1). 367

368

369 Probabilistic algorithms for classifying antibody positivity

Prior to analysis, each sample OD was standardized by dividing by the mean OD of "no sample 370 371 controls" on that plate or other plates run on the same day. This resulted in more similar 372 distributions for 2019 blood donor samples with 2020 blood donors and pregnant volunteers, 373 as well as smaller coefficients of variation amongst PCR+ COVID patients for both SPIKE and 374 RBD.

375

376 Our probabilistic learning approach consisted of evaluating different algorithms suited to ELISA data, which we compared through ten-fold cross validation (CV): logistic regression 377 378 (LOG), linear discriminant analysis (LDA), support vector machines (SVM) with a linear 379 kernel, and quadratic SVM (SVM2). Logistic regression and linear discriminant analysis both 380 model log odds of a sample being case as a linear equation with a resulting linear decision 381 boundary. The difference between the two methods is in how the coefficients for the linear 382 models are estimated from the data. When applied to new data, the output of logistic regression 383 and LDA is the probability of each new sample being a case. Support vector machines is an altogether different approach. We opted for a linear kernel, once again resulting in a linear 384 385 boundary. SVM constructs a boundary that maximally separates the classes (i.e. the margin 386 between the closest member of any class and the boundary is as wide as possible), hence points 387 lying far away from their respective class boundaries do not play an important role in shaping it. SVM thus puts more weight on points closest to the class boundary, which in our case is far 388 389 from being clear. Linear SVM has one tuning parameter C, a cost, with larger values resulting 390 in narrower margins. We tuned C on a vector of values (0.001, 0.01, 0.5, 1, 2, 5, 10) via an 391 internal 5-fold CV with 5 repeats (with the winning parameter used for the final model for the 392 main CV iteration). We also note that the natural output of SVM are class labels rather than class probabilities, so the latter are obtained via the method of Platt²⁵. 393

394

We considered three strategies for cross-validation: i) random: individuals were sampled into 395 396 folds at random, ii) stratified: individuals were sampled into folds at random, subject to 397 ensuring the balance of cases:controls remained fixed and iii) unbalanced: individuals were

sampled into folds such that each fold was deliberately skewed to under or over-represent cases

399 compared to the total sample. We sought a method with performance that was consistently 400 good across all cross-validation sampling schemes, because the true proportion of cases in the 401 test data is unknown, and we want a method that is not overly sensitive to the proportion of 402 cases in the training data. We chose to assess performance using sensitivity and specificity, as 403 well as consistency.

404

398

405 Given the good performance of all learners (described in the results), we considered the 406 prediction surface associated with each SVM, LDA, SVM-LDA ensemble, and the standard 3-407 SD, 6-SD hard decision boundaries. Note that while methods trained on both proteins can draw 408 decision contours at any angle, SD methods are limited to vertical or horizontal lines. We can see that success, or failure, of the SD cut-offs depends on how many positive and negative 409 410 cases overlap for a given measure (S or RBD) in the training sample. In the training data the 411 two classes are nearly linearly separable when each protein is considered on its own, which 412 explains good performance of 3-SD and 6-SD thresholds. However, the test data contain many 413 more points in the mid-range of S-RBD, which makes hard cut-offs a problematic choice for 414 classifying test samples.

415

We trained the learners on all 733 training samples and used these to predict the probability of anti-SARS-CoV-2 antibodies in blood donors and pregnant volunteers sampled in 2020. We inferred the proportion of the sampled population with positive antibody status each week using multiple imputation. We repeatedly (1,000 times) imputed antibody status for each individual randomly according to the ensemble prediction, and then analyzed each of the 1,000 datasets in parallel, combining inference using Rubin's rules, derived for the Wilson binomial proportion confidence interval²⁶.

423

424 Data and code availability statement

425

426 Data generated as part of the study, along with custom code for statistical analyses, is openly
427 available via our GitHub repository: https://github.com/chr1swallace/elisa-paper.

428

429 Author contributions

431	GKI	GKH and XCD designed the study and wrote the manuscript with input from co-authors. JA,					
432	TA,	TA, JD, SM, GB, MA and SA provided the study serum samples and clinical information. LH,					
433	LPV	LPV, AMM, DJS, KCI, BM and GM generated SARS-CoV-2 antigens and pseudotyped					
434	viru	viruses. MF and XCD developed the ELISA protocols and XCD generated the data. DJS and					
435	BM	performed the neutralization assay. CW and NFG executed machine learning approaches					
436	and	and statistical analyses, with input from MCh and BM. MA, SK, PP, MM, JC, MCo and JR					
437	carr	carried out wet lab experiments and assisted with data analysis.					
438							
439	Ack	nowledgments					
440							
441	We	We would like to thank the study participants and attending clinical teams. Secondly, we extend					
442	our thanks to Björn Reinius, Marc Panas, Julian Stark, Remy M. Muts and Darío Solis Sayago						
443	for their input and discussion. Funding for this work was provided by a Distinguished Professor						
444	grant from the Swedish Research Council (agreement 2017-00968) and NIH (agreement 400						
445	SUM1A44462-02). CW and NFG are funded by the Wellcome Trust (WT107881) and MRC						
446	(MC_UP_1302/5). For the purpose of Open Access, the author has applied a CC BY public						
447	copyright licence to any Author Accepted Manuscript version arising from this submission.						
448							
449	Conflict of interest						
450							
451	The study authors declare no competing interests related to the work.						
452							
453	Ref	erences					
454							
455	1.	Davis, M. M. A Prescription for Human Immunology. Immunity vol. 29 835-838					
456		(2008).					
457	2.	Sekine, T. et al. Robust T Cell Immunity in Convalescent Individuals with					
458		Asymptomatic or Mild COVID-19. Cell (2020) doi:10.1016/j.cell.2020.08.017.					
459	3.	Cervia, C. et al. Systemic and mucosal antibody responses specific to SARS-CoV-2					
460		during mild versus severe COVID-19. J. Allergy Clin. Immunol. (2020)					
461		doi:10.1016/j.jaci.2020.10.040.					
462	4.	Robbiani, D. F. et al. Convergent Antibody Responses to SARS-CoV-2 Infection in					
463		Convalescent Individuals. Nature (2020) doi:10.1101/2020.05.13.092619.					
464	5.	Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for greater than					

465 eight months after infection. bioRxiv (2020). 466 6. Gudbjartsson, D. F. et al. Spread of SARS-CoV-2 in the Icelandic Population. N. Engl. 467 J. Med. (2020) doi:10.1056/nejmoa2006100. Özçürümez, M. K. et al. SARS-CoV-2 antibody testing-questions to be asked. J. 468 7. 469 Allergy Clin. Immunol. (2020) doi:10.1016/j.jaci.2020.05.020. 470 8. Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in 471 adults. Nature (2020) doi:10.1038/s41586-020-2639-4. 472 9. Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. 473 N. Engl. J. Med. (2020) doi:10.1056/nejmoa2022483. 474 Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity 10. 475 and correlates of severity. Science (80-.). (2020) doi:10.1126/science.abd4250. Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. British 476 11. 477 Medical Journal (2006) doi:10.1136/bmj.332.7549.1080. MacCallum, R. C., Zhang, S., Preacher, K. J. & Rucker, D. D. On the practice of 478 12. dichotomization of quantitative variables. Psychol. Methods (2002) doi:10.1037//1082-479 480 989x.7.1.19. 481 Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion 13. 482 conformation. Science (80-.). (2020) doi:10.1126/science.aax0902. 483 Hanke, L. et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor 14. 484 interaction. Nat. Commun. (2020) doi:10.1038/s41467-020-18174-5. 15. Herzenberg, L. A. & Herzenberg, L. A. Toward a layered immune system. Cell (1989) 485 486 doi:10.1016/0092-8674(89)90748-4. 487 Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. 16. 488 Nat. Med. (2020) doi:10.1038/s41591-020-0897-1. Eto, D. et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and 489 17. 490 redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS 491 One 6, e17739 (2011). Dienz, O. et al. The induction of antibody production by IL-6 is indirectly mediated by 492 18. 493 IL-21 produced by CD4 + T cells. J. Exp. Med. (2009) doi:10.1084/jem.20081571. Maeda, K., Mehta, H., Drevets, D. A. & Coggeshall, K. M. IL-6 increases B-cell IgG 494 19. 495 production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood (2010) doi:10.1182/blood-2009-07-230631. 496 497 20. Beagley, K. W. et al. Interleukins and IgA synthesis. Human and murine interleukin 6 498 induce high rate IgA secretion in IgA-committed B cells. J. Exp. Med. (1989)

499		doi:10.1084/jem.169.6.2133.
500	21.	Bartosch, B. et al. In vitro assay for neutralizing antibody to hepatitis C virus:
501		Evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. U. S. A.
502		(2003) doi:10.1073/pnas.2335981100.
503	22.	Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19
504		severity and survival. Nat. Med. (2020) doi:10.1038/s41591-020-1051-9.
505	23.	Seow, J. et al. Longitudinal evaluation and decline of antibody responses in SARS-
506		CoV-2 infection. Nat. Microbiol. (2020) doi:10.1101/2020.07.09.20148429.
507	24.	Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-
508		CoV-2 infections. Nat. Med. (2020) doi:10.1038/s41591-020-0965-6.
509	25.	Platt, J. & others. Probabilistic outputs for support vector machines and comparisons to
510		regularized likelihood methods. Adv. large margin Classif. (1999).
511	26.	Lott, A. & Reiter, J. P. Wilson Confidence Intervals for Binomial Proportions With
512		Multiple Imputation for Missing Data. Am. Stat. (2020)
513		doi:10.1080/00031305.2018.1473796.



Figure 1: Anti-SARS-CoV-2 Ab phenotypes in COVID-19 patients, PCR+ individuals, blood donors and pregnant women. (A) OD450nm optical density for anti-S and -RBD IgM, IgG and IgA responses in SARS-CoV-2 PCR+ individuals (n=105), blood donors (BD, n=500) and pregnant women (PW, n=500). A small number of controls for each assay are represented by open circles. (B) Circulating IL-6 levels in serum are associated with disease severity. (C) Anti-viral antibody levels are associated with disease severity, most pronounced for anti-viral IgA. Anti-S and RBD responses are graphed together. (D) Two discordant longitudinal profiles of seroconversion and neutralisation capacity are shown in hospitalized COVID-19 patients. (E) *In vitro* pseudotyped virus neutralization ID₅₀ titers are associated with disease severity, with the highest titers observed in Cat 3 (ICU) patients. n=48 SARS-CoV-2 PCR+ individuals were analyzed in duplicate. (E) Comparison of anti-S IgG levels between PCR+ individuals, blood donors (BD) and pregnant women (PW). 3 and 6 SD cut-offs are shown.





(A) Distribution of Anti-S and RBD IgG OD values for 595 historical controls (blood donors from Spring 2019). (B) Random sub-sampling of non-overlapping negative controls illustrates how the range of negative control (C) values can influence a conventional test cut-off, here 6 SD from the mean of the respective C groups. In the test data, depending on the control values used to set the test threshold for positivity, SP estimates vary by 40%. Blood donor and pregnant women sample values are used as an example. Anti-S IgG values are shown. (C) Comparison of probabilistic algorithms suited to ELISA measurements. Logistic regression (LOG), linear discriminant analysis (LDA), support vector machines (SVM) and quadratic SVM. Learners were trained using anti-S and RBD IgG data from 595 negative control values and 138 SARS-CoV-2 PCR+ individuals. Ensemble (*ENS*) learners were generated from the output of SVM-LDA, SVM2-LDA and LOG-LDA, as described. (D) Comparisons of specificity and sensitivity for the different probabilistic methods (and SD thresholding) using different cross-validation strategies. (E) *ENS* probabilities when applied to healthy donor test data, providing a highly sensitive, specific and consistent multi-dimensional solution to the problem of low responders, and assigning each data point a probability of being positive.

Table	1 –	Study	samples
-------	-----	-------	---------

SARS-CoV-2 PCR+ individuals [§]	<i>n=</i> 105	
Females	44 (41.9%)	
Males	61 (58.1%)	
Median age (years)	53.0 (49-61)	
Females	51.5 (48-56.2)	
Males	55.0 (49-63)	
Non-hospitalized (<i>n</i> =)	53	
Females, males	28, 25	
Hospitalized patients (<i>n</i> =)	31	
Females, males	12, 17	
Intensive care (ICU) patients (<i>n</i> =)	21	
Females, males	3, 17	
SARS-CoV2+ PCR (<i>n</i> =)	105	
Sample collection dates	March-May 2020	
SARS-CoV-2 PCR+ KI hospital staff	<i>n=</i> 33	
Sample collection dates	July 2020	
Blood donors	<i>n=5</i> 00	
Sample collection dates	Weeks 17-21 (March-August) 2020	
Pregnant women	<i>n=5</i> 00	
Sample collection dates	Weeks 17-21 (March-May) 2020	
Historical blood donors	<i>n=</i> 595	
Sample collection dates	March-June 2019	
ECV+ donors	<i>n=</i> 20	
Sample collection dates	July-December 2019	
[§] Under the care of Karolinska University Hospital		

No additional metadata available for any samples



Figure S1: Antibody phenotypes in PCR+ individuals and healthy participants

(A) Study samples used for assay development. (B) Anti-S IgM reactivity observed in a random subset of historical controls. Binding was confirmed in these samples in an independent experiment. No reproducible IgG reactivity to S trimers of the RBD was observed across all historical controls in the study. (C) Serial dilution of n=30 random PCR+ individuals. ECV+ (n=4) controls are shown in red.
 (D) Spearman's rank correlation of PCR+ dataset features and antibody levels. DOB - *date of birth*; d-p SymO - *days post-symptom onset*; d-p PCR - *days post SARS-CoV-2+ PCR*; PSV ID50 - *neutralizing titer*. (E) Adjusted fold-change compared to Category 1 PCR+ individuals. The effects of age (DOB), sex, days from PCR test were considered.